Ending malaria in Nigeria: Why local manufacturing is now the decisive front
Malaria no longer persists for lack of solutions—it endures because the systems required to deliver those solutions remain fragile, uneven, and too often externally dependent. As World Malaria Day 2026
Malaria no longer persists for lack of solutions—it endures because the systems required to deliver those solutions remain fragile, uneven, and too often externally dependent. As World Malaria Day 2026 rallies the world around the theme “Now We Can. Now We Must,” Nigeria’s challenge is no longer scientific discovery but strategic execution: how to ensure that proven, life-saving interventions consistently reach those who need them most.
Nowhere is that urgency more pronounced than in Nigeria, the epicentre of the global malaria burden. According to the World Health Organization, the country accounts for approximately 27 per cent of malaria cases worldwide and nearly one in three malaria-related deaths. These figures are not abstract—they translate into overwhelmed clinics, missed school days, lost productivity, and, most devastatingly, preventable deaths among children under five and pregnant women.
Against this backdrop, Emzor Pharmaceutical Industries Limited is advancing a proposition that reframes the malaria fight from a cycle of treatment to a question of national capacity. Its position is clear: eliminating malaria in Nigeria will require more than distributing medicines—it will demand building a resilient, self-sufficient pharmaceutical ecosystem capable of sustaining access at scale. At the heart of this argument is local manufacturing. For decades, Nigeria’s dependence on imported medicines has exposed its health system to global supply chain disruptions, currency volatility, and shifting geopolitical priorities. In such a system, access to essential drugs can fluctuate unpredictably, undermining even the most well-funded health interventions.
“Local manufacturing is no longer optional—it is central to our national health security,” said Uzoma Ezeoke, Executive Director at Emzor. Her statement captures a growing consensus that health outcomes are increasingly tied to industrial policy. When medicines are produced domestically, availability becomes more predictable, pricing more stable, and quality more controllable. In effect, local production transforms access from a variable into a constant.
But Emzor’s advocacy goes further, drilling down into a less visible yet critical layer of pharmaceutical production: Active Pharmaceutical Ingredients (APIs). While finished drugs are widely distributed, the chemical compounds that give them efficacy are still overwhelmingly imported. This structural gap, industry experts argue, is one of the most significant vulnerabilities in Nigeria’s healthcare supply chain. For Emzor’s Chairman, Emeka Okoli, addressing this gap is both an economic and public health imperative. Developing local API manufacturing would anchor the entire pharmaceutical value chain within the country, reducing exposure to external shocks while unlocking new opportunities for industrial growth. It would also enable stricter regulatory oversight, ensuring that medicines consistently meet global standards.
More importantly, it would mark a shift from dependency to capability. A Nigeria that produces its own APIs is not just treating malaria—it is building the infrastructure to confront future health challenges with greater autonomy and resilience. Yet even the most sophisticated manufacturing strategy must ultimately be judged by its impact at the patient level. Here, the conversation moves from factories to families, from production lines to bedside realities.
One of the enduring challenges in malaria treatment is not merely access to drugs but their usability, particularly for children. Young patients often struggle with conventional tablet formulations, leading to incomplete dosing and reduced treatment effectiveness. Recognising this, Emzor has prioritised innovations that respond directly to these barriers. Among them is Lokmal Dispersible Tablets, a child-friendly antimalarial designed for children aged three months to five years. The dispersible format allows the medication to dissolve easily in water or milk, simplifying administration and improving adherence. In practical terms, it transforms treatment from a stressful ordeal into a manageable routine for caregivers, significantly enhancing the likelihood of successful outcomes.
Equally critical is preventive care for pregnant women, a group particularly vulnerable to malaria-related complications. Through Maldox, used in Intermittent Preventive Treatment in pregnancy (IPTp), Emzor is contributing to efforts aimed at reducing maternal and neonatal risks. By preventing infection rather than merely responding to it, such interventions address malaria’s impact at one of its most sensitive junctures. These products reflect a broader philosophy: that effective healthcare solutions must be designed with the realities of patients and caregivers in mind. Accessibility is not just about physical availability; it is about ease of use, cultural compatibility, and the ability to integrate seamlessly into everyday life.
Read Also: Nigerian Navy deploys 10 ships,helicopters for sea exercise
Still, the scale of Nigeria’s malaria burden means that no single company—regardless of capacity—can drive elimination alone. The path forward, as Emzor emphasises, lies in coordinated action across multiple sectors. Government policies must incentivise local manufacturing and support infrastructure development. Development partners must align funding with long-term capacity building rather than short-term interventions. Private sector actors must invest not only in production but also in research and innovation. “The time to move from commitment to execution is now,” Okoli stated, echoing the urgency embedded in this year’s global theme. It is a call that resonates beyond corporate boardrooms, extending to policymakers, investors, and public health practitioners alike.
For Nigeria, the implications of such coordination are profound. A successful transition toward pharmaceutical self-reliance would not only accelerate malaria elimination but also strengthen the broader health system, making it more responsive to future crises. It would generate employment, stimulate economic growth, and position the country as a regional leader in pharmaceutical manufacturing. Conversely, failure to act decisively risks perpetuating a cycle of dependency in which progress remains contingent on external factors. In such a scenario, malaria would continue to exploit systemic weaknesses, claiming lives that could otherwise be saved. There is, however, a growing sense that the conditions for change are converging. Advances in medical science have provided the necessary tools. Increased awareness has sharpened the focus on vulnerable populations. What remains is the political will and strategic investment required to align these elements into a coherent, sustainable system.
As World Malaria Day 2026 is commemorated, the message emerging from Nigeria is both pragmatic and urgent: ending malaria is no longer a distant aspiration but an achievable goal—provided the country is willing to invest in the structures that make success possible. In the final analysis, the fight against malaria is evolving from a question of “what works” to “what lasts.” Medicines exist. Strategies are proven. The real challenge lies in building a system that ensures these solutions are available, affordable, and effective—every time, for everyone. That is the difference between managing malaria and ending it. And, as this moment makes clear, it is a difference Nigeria can no longer afford to postpone.
